Stay updated with breaking news from Program Subsidiary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus La
13.12.2022 - Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases ...